Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 13/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693803 | 0.85 | POLB (0.47) | IDO1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4039861 | 0.81 | IDO1 (0.37) | PKMIDO1SMN1; SMN2LMNATDO2 | |
| SCHEMBL16321669 | 0.81 | IDO1 (0.50) | IDO1TDO2 | |
| SCHEMBL6046626 | 0.81 | IDO1 (0.49) | PKMIDO1TDO2IKBKEMEN1 | |
| SCHEMBL16321277 | 0.78 | IDO1 (0.39) | PKMIDO1TDO2IKBKEMAPT | |
| SCHEMBL16321293 | 0.78 | IDO1 (0.37) | PKMIDO1TDO2 | |
| SCHEMBL9995495 | 0.77 | TSHR (0.38) | IDO1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL16322251 | 0.77 | PKM (0.42) | PKMIDO1SMN1; SMN2TDO2MAPT | |
| SCHEMBL16321109 | 0.76 | IDO1 (0.42) | PKMIDO1TDO2IKBKEMAPT | |
| SCHEMBL16321603 | 0.75 | NPC1 (0.44) | PKMIDO1SMN1; SMN2LMNAIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2014-12-25 | — | — | US | claimed |
| EP-1879573-A4 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORP (US) | 2009-07-08 | — | — | EP | claimed |
| EP-1879573-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006122150-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2006-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377292-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME | IDO1, IDO2, INMT | PKM 1661/4885IDO1 1/4885SMN1; SMN2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.